MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s42255-026-01643-4

Медицинская библиотека · Nature metabolism · 2026

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.

Koning Mijra, Kovynev Artemiy, Fondevila Marcos F, Ruhe Eliza J M, Mommersteeg Michiel C, Ramakers Christian, Hutten Barbara A, Verwer Bart, Vlug Marije, Kuiper Teaco, van den Berg Maarten, Vrieze Anne, Bizino Maurice, van den Beld Annewieke, Berk Luuk, Boerlage Thomas, Augustijn Quinten J J, Brouwer Willem Pieter, Chen Weena J, Cahen Djuna, Verdonk Robert, de Jonge Wouter J, Ramsoekh Sandjai, Doukas Michail, Vermorgen Sanne M M, Verheij Joanne, Beuers Ulrich, Takkenberg R B, Bergman Jacques J G, D'Haens Geert R A M, Drenth Joost P H, Tchkonia Tamar, Schnabl Bernd, Kirkland James L, Meijnikman Abraham S

СтатьяПеревод в очереди

Аннотация

Cellular senescence plays an important role in hepatic inflammation and fibrosis1-3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (-1.43 ± 1.22 versus -0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 .

Для цитирования: Koning Mijra, Kovynev Artemiy, Fondevila Marcos F, Ruhe Eliza J M, Mommersteeg Michiel C, Ramakers Christian, Hutten Barbara A, Verwer Bart, Vlug Marije, Kuiper Teaco, van den Berg Maarten, Vrieze Anne, Bizino Maurice, van den Beld Annewieke, Berk Luuk, Boerlage Thomas, Augustijn Quinten J J, Brouwer Willem Pieter, Chen Weena J, Cahen Djuna, Verdonk Robert, de Jonge Wouter J, Ramsoekh Sandjai, Doukas Michail, Vermorgen Sanne M M, Verheij Joanne, Beuers Ulrich, Takkenberg R B, Bergman Jacques J G, D'Haens Geert R A M, Drenth Joost P H, Tchkonia Tamar, Schnabl Bernd, Kirkland James L, Meijnikman Abraham S. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.. Nature metabolism. 2026. DOI: 10.1038/s42255-026-01643-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.